first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
Published 3 years ago • 118 plays • Length 4:32Download video MP4
Download video MP3
Similar videos
-
2:40
regorafenib plus pembrolizumab for first-line treatment of advanced hcc
-
4:07
80mg regorafenib plus pembrolizumab for 1l hcc
-
1:49
regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma
-
2:53
renobate: investigating regorafenib plus nivolumab as 1st-line therapy for unresectable hcc
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
3:11
regorafenib in advanced hcc
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
4:30
regorafenib following first-line systemic therapy in hcc
-
1:03
dr. musher discusses the role of regorafenib in advanced hcc
-
6:56
prior rt may potentially enhance treatment of mss-crc with regorafenib and pembrolizumab
-
3:22
keynote-224: pembrolizumab monotherapy for previously untreated hcc
-
1:15
regonext: 2l regorafenib in patients with unresectable hcc who have progressed on atezo-bev
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
7:01
global use of regorafenib in hcc
-
3:48
clinical experience with regorafenib in hcc
-
4:14
the use of regorafenib in clinical practice
-
4:28
proactive side effect management with regorafenib
-
2:04
dr. bruix on regorafenib in second-line hcc